US-based biotechnology company, PanTheryx, in partnership with Zuellig Pharma, a healthcare company in Asia, announced the launch of innovation of DiaResQ for diarrhea relief in Cambodia.
The new product DiaResQ, launched by PanTheryx, which is focused on addressing serious GI-related health conditions, is neither a drug nor over-the-counter medicine is a nutritional intervention that contains immune factors, micro as well as macronutrients that work with the body to address the underlying cause of diarrhea.
A majority of cases of pediatric diarrhea, a disease that claims the lives of thousands every year have been resolved with DiaResQ’s launch in Cambodia, and now clinicians have access to the highly effective and clinically proven product.
Pediatric diarrhea is the second leading cause of death for children under five, accounting for approximately 8 percent of deaths worldwide. If proven prevention and management interventions were made routinely available to all Cambodian children, many of these deaths could have been avoidable.
The results in clinical trials showed that a majority of cases of pediatric diarrhea have been resolved after one day of use. Over 1,000 children and adults have been collectively enrolled in the clinical trials and no serious adverse events attributable to DiaResQ have been reported in it.
